678 related articles for article (PubMed ID: 10935988)
1. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
[TBL] [Abstract][Full Text] [Related]
2. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
[TBL] [Abstract][Full Text] [Related]
3. The effect of vaccination on the epidemiology of varicella zoster virus.
Edmunds WJ; Brisson M
J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
[TBL] [Abstract][Full Text] [Related]
4. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
[TBL] [Abstract][Full Text] [Related]
5. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen.
Sauerbrei A; Wutzler P
Clin Lab; 2009; 55(1-2):1-7. PubMed ID: 19350844
[TBL] [Abstract][Full Text] [Related]
6. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
8. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
Berger R; Luescher D; Just M
Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
[TBL] [Abstract][Full Text] [Related]
9. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.
Breuer J; Schmid DS; Gershon AA
J Infect Dis; 2008 Mar; 197 Suppl 2():S147-51. PubMed ID: 18419389
[TBL] [Abstract][Full Text] [Related]
10. Varicella vaccination in HIV-1-infected children after immune reconstitution.
Bekker V; Westerlaken GH; Scherpbier H; Alders S; Zaaijer H; van Baarle D; Kuijpers T
AIDS; 2006 Nov; 20(18):2321-9. PubMed ID: 17117018
[TBL] [Abstract][Full Text] [Related]
11. Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment.
Balfour HH
Scand J Infect Dis Suppl; 1991; 80():69-74. PubMed ID: 1666447
[TBL] [Abstract][Full Text] [Related]
12. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.
Krause PR; Klinman DM
Nat Med; 2000 Apr; 6(4):451-4. PubMed ID: 10742154
[TBL] [Abstract][Full Text] [Related]
13. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster.
Breuer J; Whitley R
Herpes; 2007 Sep; 14 Suppl 2():25-9. PubMed ID: 17939892
[TBL] [Abstract][Full Text] [Related]
14. Persistence of immunity to live attenuated varicella vaccine in healthy adults.
Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A
Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses to early antigens of varicella-zoster virus (VZV) during varicella and zoster.
Namazue J; Kato T; Yamanishi K; Takahashi M; Asano Y; Muraki R
Biken J; 1986 Dec; 29(3-4):91-7. PubMed ID: 3039973
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
[TBL] [Abstract][Full Text] [Related]
17. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
[TBL] [Abstract][Full Text] [Related]
18. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia.
Gao Z; Gidding HF; Wood JG; MacIntyre CR
Epidemiol Infect; 2010 Apr; 138(4):457-68. PubMed ID: 19781116
[TBL] [Abstract][Full Text] [Related]
19. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.
Sauerbrei A; Wutzler P
J Clin Microbiol; 2006 Sep; 44(9):3094-7. PubMed ID: 16954232
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin subclass antibodies to varicella-zoster virus.
Asano Y; Hiroishi Y; Itakura N; Hirose S; Kajita Y; Nagai T; Yazaki T; Takahashi M
Pediatrics; 1987 Dec; 80(6):933-6. PubMed ID: 2825110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
